SCHEMBL13453290

SCHEMBL13453290

Cc1ccc2nc(-c3ccc([18F])cc3)sc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 16/20 1.00
MAPT P10636 4/20 0.72
KDM4E B2RXH2 3/20 0.72
NPC1 O15118 3/20 0.72
RAB9A P51151 3/20 0.72
GLA P06280 2/20 0.72
GAA P10253 2/20 0.72
RORC P51449 2/20 0.69
MEN1 O00255 2/20 0.69
ALDH1A1 P00352 2/20 0.69
KMT2A Q03164 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
HSP90AA1 P07900 1/20 0.69
HPGD P15428 1/20 0.69
SNCA P37840 1/20 0.68
SULT1A1 P50225 1/20 0.68
TP53 P04637 1/20 0.59
LMNA P02545 1/20 0.58
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24038234 0.93 APP (0.86) APPMAPTKDM4ENPC1RAB9A
SCHEMBL12422070 0.92 APP (0.84) APPMAPTKDM4ENPC1RAB9A
SCHEMBL15425178 0.90 APP (0.82) APPMAPTKDM4ENPC1RAB9A
SCHEMBL12422217 0.90 MAPT (0.81) APPMAPTKDM4ENPC1RAB9A
SCHEMBL24185755 0.85 APP (0.72) APPMAPTKDM4ENPC1RAB9A
SCHEMBL24038235 0.84 APP (0.72) APPMAPTKDM4ENPC1RAB9A
SCHEMBL492713 0.84 APP (1.00) APPMAPTKDM4ENPC1RAB9A
SCHEMBL5349180 0.84 MAPT (0.72) APPMAPTKDM4ENPC1RAB9A
SCHEMBL2244143 0.84 APP (0.72) APPMAPTKDM4ENPC1RAB9A
SCHEMBL12355589 0.84 MAPT (0.72) APPMAPTKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120263646-A1 IMAGING AGENTS AND THEIR USE FOR THE DIAGNOSTIC IN VIVO OF NEURODEGENERATIVE DISEASES, NOTABLY ALZHEIMER'S DISEASE AND DERIVATIVE DISEASES GUERBET (FR) 2012-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120263646-A1 IMAGING AGENTS AND THEIR USE FOR THE DIAGNOSTIC IN VIVO OF NEURODEGENERATIVE DISEASES, NOTABLY ALZHEIMER'S DISEASE AND DERIVATIVE DISEASES SNCA, PSEN2, CLN6 APP 10/4885MAPT 4/4885KDM4E 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.